Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has provided an update.
Hangzhou Tigermed Consulting Co., Ltd. announced an update to its final cash dividend for the year ended December 31, 2024, with a payment date set for July 11, 2025. The dividend is declared at RMB 3 per 10 shares, with a corresponding payment in Hong Kong dollars for shareholders registered in Hong Kong. The announcement also details the withholding tax rates applicable to different categories of shareholders, impacting non-resident and mainland individual investors. This update reflects the company’s commitment to shareholder returns and may influence investor sentiment positively.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$38.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. operates in the consulting industry, focusing on providing clinical trial services and contract research organization (CRO) solutions. The company primarily serves the pharmaceutical and biotechnology sectors, offering expertise in clinical development and regulatory compliance.
Average Trading Volume: 4,296,181
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.25B
For an in-depth examination of 3347 stock, go to TipRanks’ Overview page.